Kintara Therapeutics, Inc (KTRA) PT Raised to $7 at Aegis Capital
- S&P 500, Dow slip as focus turns to tech earnings
- Kansas City Southern (KSU) Soars as Bidding War Brews After Canadian National Railway (CNI) Makes a $33.7 Billion Offer
- Analysts Positive, Raise PTs as IBM (IBM) Tops Market Estimates and Reaffirms Guidance
- Boeing (BA) Down 3% After CFO - Aged 54 - Retires, Seen as an 'Odd' Move
- Tesla (TSLA): Problems in China Mounting as Communist Party Officials Ask Company to 'Respect Chinese Consumers and Comply with Local Laws'
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Aegis Capital analyst Nathan Weinstein raised the price target on Kintara Therapeutics, Inc (NASDAQ: KTRA) to $7.00 (from $6.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Osisko Gold Royalties Ltd. (OR:CN) (OR) PT Raised to Cdn$23 at Stifel Canada
- Fiore Gold Ltd (F:CN) (FIOGF) PT Lowered to Cdn$2.30 at Stifel Canada
- B.Riley Assumes Colony Northstar Credit Real Estate (CLNC) at Buy
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!